Moreover, 6-OH-DOPA selectively inhibited cell proliferation in BRCA1-depleted triple-negative breast cancer (TNBC) cells and in BRCA-deficient AML and CML patient cells. This evidence concerns the gene BRCA1 and chronic myelogenous leukemia, BCR-ABL1 positive.